Insmed Inc (INSM) — 13F Filings Explorer (Q2 2026)

INSM ranks #825 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

INSM is a top-conviction position for Darwin Global Management, Ltd. — at 17.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in INSM belongs to FMR LLC, but the position matters far more to Darwin Global Management, Ltd., who has 17.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Assenagon Asset Management S.A. has added to its INSM position for two straight quarters, increasing it by $134.2M to reach $144.6M today.

Concurrent Investment Advisors, LLC has trimmed its INSM position for two straight quarters, cutting it by $597.0K while still holding $243.7K.

INSM is down 6.6% today, but institutions show net buying of $4.5B this quarter — a divergence between today's price move and the underlying institutional flow.

INSM reported a net loss of $875.3M over the trailing twelve months.

• Not yet profitable — net loss of $875.3M over the trailing twelve months
• Revenue grew 185.8% year over year
• Net income improved year over year, from -$1.0B to -$875.3M
• Operating cash flow was negative, using $935.0M in cash
• Current ratio of 3.83x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.06x equity — a highly leveraged balance sheet worth noting